Einloggen
Einloggen
Oder einloggen mit
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Registrieren
Oder einloggen mit
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

GLAUKOS CORPORATION

(A14VCK)
  Bericht
Verzögert Nyse  -  19:00 25.11.2022
47.13 USD   -0.65%
03.11.Glaukos Corporation : Needham & Co. bekräftigt seine Kaufempfehlung
MM
03.11.Glaukos Corporation : Piper Sandler bekräftigt seine neutrale Bewertung
MM
02.11.Glaukos Corporation gibt Umsatzprognose für das Jahr 2022 ab
CI
ÜbersichtKurseChartsNewsRatingsTermineUnternehmenFinanzenAnalystenschätzungenRevisionenDerivateFonds 
ÜbersichtAlle NewsAnalystenempfehlungenAndere SprachenPressemitteilungenOffizielle PublikationenBranchen-News
Nachrichten in anderen Sprachen über GLAUKOS CORPORATION
15.11.Glaukos : Investor Presentation November 2022
15.11.Glaukos Corp : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
07.11.Glaukos Announces Participation in the Stephens Annual Investment Conference
04.11.GLAUKOS CORP Management's Discussion and Analysis of Financial Condition and Results o..
02.11.Glaukos : Q3 Earnings Snapshot
02.11.Transcript : Glaukos Corporation, Q3 2022 Earnings Call, Nov 02, 2022
02.11.Earnings Flash (GKOS) GLAUKOS CORPORATION Posts Q3 Revenue $71.3M
02.11.Earnings Flash (GKOS) GLAUKOS CORPORATION Posts Q3 Loss $-0.45
02.11.Glaukos Corp : Results of Operations and Financial Condition, Regulation FD Disclosure, Fi..
02.11.Glaukos Corporation Announces Third Quarter 2022 Financial Results
02.11.Glaukos Corporation Provides Revenue Guidance for the Year 2022
02.11.Glaukos Corporation Reports Earnings Results for the Third Quarter and Nine Months Ende..
12.10.Glaukos to Release Third Quarter 2022 Financial Results after Market Close on November ..
28.09.Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2022 American Aca..
07.09.Coupa Software, Glaukos rise; Occidental Petroleum falls
07.09.Sector Update: Health Care Stocks Gaining Steam in Late Trade
07.09.Sector Update: Health Care Stocks Rebounding Wednesday After Long Retreat
07.09.Top Midday Gainers
07.09.Glaukos Says Results of Phase 3 Trials of iDose TR Met Primary Efficacy Endpoints, Plan..
07.09.Sector Update: Health Care Stocks Mixed Premarket Wednesday
07.09.Glaukos Says Results of Phase 3 Trials of iDose TR Met Primary Efficacy Endpoints, Plan..
07.09.Glaukos Corp : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
07.09.Glaukos Announces Positive Topline Outcomes for Both Phase 3 Pivotal Trials of iDose TR..
07.09.Glaukos Corporation Announces Positive Topline Outcomes for Both Phase 3 Pivotal Trials..
06.09.Glaukos Reports 1 Million Uses of iStent Products
06.09.Glaukos Announces More Than 1 Million iStent® Technologies Implanted Worldwide
29.08.Burns & Levinson Represents iVeena Delivery Systems, Inc. in Strategic Licensing Agreem..
24.08.Sector Update: Health Care Stocks Inching Higher Near Close
24.08.Sector Update: Health Care Stocks Left Grappling for Direction in Uncertai..
24.08.Glaukos Announces Participation in the Wells Fargo Healthcare Conference
24.08.Glaukos Secures License to Investigational Corneal Disorder Treatment
24.08.Glaukos Licenses Iveena’S Investigational Keratoconus Therapy
08.08.Insider Sell: Glaukos
05.08.GLAUKOS CORP Management's Discussion and Analysis of Financial Condition and Results o..
03.08.Glaukos : Q2 Earnings Snapshot
03.08.Glaukos : Announces Second Quarter 2022 Financial Results - Form 8-K
03.08.Transcript : Glaukos Corporation, Q2 2022 Earnings Call, Aug 03, 2022
03.08.Glaukos Corp : Results of Operations and Financial Condition, Regulation FD Disclosure, Fi..
03.08.Earnings Flash (GKOS) GLAUKOS CORPORATION Reports Q2 Revenue $72.7M
03.08.Earnings Flash (GKOS) GLAUKOS CORPORATION Reports Q2 Loss $-1.21
03.08.Glaukos Corporation Announces Second Quarter 2022 Financial Results
03.08.Glaukos Announces FDA 510(k) Clearance of iStent infinite®
03.08.Glaukos Corporation Reports Earnings Results for the Second Quarter and Six Months Ende..
03.08.Glaukos Corporation Reports Earnings Results for the Second Quarter and Six Months Ende..
03.08.Glaukos Corporation Revises Sales Guidance for the Year 2022
03.08.Glaukos Corporation Announces FDA 510(k) Clearance of iStent Infinite
13.07.Glaukos to Release Second Quarter 2022 Financial Results after Market Close on August 3
12.07.Sector Update: Health Care Stocks Drop on Tuesday
12.07.Glaukos Shares Rise After Stifel Upgrade
12.07.Sector Update: Health Care Stocks Drifting Lower This Afternoon
08.06.Glaukos Corp : Submission of Matters to a Vote of Security Holders (form 8-K)
02.06.Glaukos Announces Participation in the William Blair Growth Stock Conference
23.05.Glaukos Corp : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
20.05.Glaukos Announces Participation in the Piper Sandler Virtual Ophthalmology Symposium
05.05.GLAUKOS CORP Management's Discussion and Analysis of Financial Condition and Results o..
04.05.Glaukos : Q1 Earnings Snapshot
04.05.Earnings Flash (GKOS) GLAUKOS CORPORATION Reports Q1 Revenue $67.7M, vs. Street Est of ..
04.05.Earnings Flash (GKOS) GLAUKOS CORPORATION Reports Q1 Loss $-0.38, vs. Street Est of $-0..
04.05.Transcript : Glaukos Corporation, Q1 2022 Earnings Call, May 04, 2022
04.05.Glaukos Corp : Results of Operations and Financial Condition, Regulation FD Disclosure, Fi..
04.05.Glaukos Corporation Announces First Quarter 2022 Financial Results
04.05.Glaukos Corporation Updates Sales Guidance for the Year 2022
04.05.Glaukos Corporation Reports Earnings Results for the First Quarter Ended March 31, 2022
21.04.Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2022 American Soc..
20.04.Glaukos Announces the Release of its 2021 Sustainability Report
13.04.Glaukos to Release First Quarter 2022 Financial Results after Market Close on May 4
14.03.Glaukos Says It Has Started Phase 2 Clinical Program for Eye Disease Treatment; Shares ..
14.03.Glaukos Announces Commencement of Phase 2 Corneal Health Clinical Program for Third-Gen..
14.03.Glaukos Announces Commencement of Phase 2 Corneal Health Clinical Program for Third-Gen..
02.03.Glaukos : Investor Presentation March 2022
02.03.Glaukos Corp : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
28.02.GLAUKOS CORP MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS O..
23.02.Sector Update: Health Care Stocks Unable to Retain Midday Rise
23.02.Sector Update: Health Care Stocks Higher in Wednesday Trading
22.02.Glaukos : Q4 Earnings Snapshot
22.02.Glaukos : Announces Fourth Quarter and Full Year 2021 Financial Results - Form 8-K
22.02.Transcript : Glaukos Corporation, Q4 2021 Earnings Call, Feb 22, 2022
22.02.Earnings Flash (GKOS) GLAUKOS CORPORATION Reports Q4 Revenue $73.2M, vs. Street Est of ..
22.02.Earnings Flash (GKOS) GLAUKOS CORPORATION Reports Q4 Loss $-0.31, vs. Street Est of $-0..
22.02.Glaukos Corp : Results of Operations and Financial Condition, Regulation FD Disclosure, Fi..
22.02.Glaukos Corporation Reports Earnings Results for the Full Year Ended December 31, 2021
22.02.Glaukos Corporation Announces Fourth Quarter and Full Year 2021 Financial Results
22.02.Glaukos Corporation Provides Sales Guidance for the Year 2022
21.02.Trackinsight: Investors exit Medical Innovation ETFs
21.02.Trackinsight: Les investisseurs quittent les ETF sur l’innovation médicale
07.02.Glaukos : Announces Executive Leadership Changes - Form 8-K
07.02.Glaukos Corp : Change in Directors or Principal Officers, Regulation FD Disclosure, Financ..
07.02.Glaukos Announces Executive Leadership Changes
07.02.Glaukos Corporation Announces Executive Changes
07.02.Glaukos Corporation Announces Executive Changes
04.02.North American Morning Briefing: Amazon.com, Snap -2-
01.02.Glaukos Corporation to Release Fourth Quarter and Full Year 2021 Financial Results afte..
19.01.North American Morning Briefing: Stock Futures -3-
11.01.Transcript : Glaukos Corporation Presents at JPMorgan 40th Annual Healthcare ..
11.01.Glaukos Enrolls First Patient in Two Phase 2 Eye Disease Trials, Says iDose TR Study Sh..
11.01.Glaukos : Investor Presentation January 2022
11.01.Glaukos Corp : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
11.01.Glaukos' iDose® TR Demonstrates Sustained IOP Reduction and Favorable Safety Profile Ov..
11.01.Glaukos Announces First Patient Enrolled in Phase 2 Clinical Trial for Dry Eye Disease
11.01.Glaukos Announces First Patient Enrolled in Phase 2 Clinical Trial for Presbyopia
Anstehende Termine für GLAUKOS CORPORATION